Koers American Oriental Bioengineering, Inc. Other OTC
Aandelen
AOBI
US0287315032
Farmaceutische producten
Omzet 2011 | 213 mln. 199 mln. | Omzet 2012 | 145 mln. 136 mln. | Marktkapitalisatie | 13,35 mln. 12,49 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2011 | -67 mln. -62,69 mln. | Nettowinst (verlies) 2012 | -59 mln. -55,2 mln. | EV/omzet 2011 | 0,5 x |
Nettoschuld 2011 | 63,31 mln. 59,23 mln. | Nettoschuld 2012 | 49,49 mln. 46,3 mln. | EV/omzet 2012 | 0,43 x |
K/w-verhouding 2011 |
-0,62
x | K/w-verhouding 2012 |
-0,22
x | Werknemers | - |
Dividendrendement 2011 * |
-
| Dividendrendement 2012 |
-
| Vrij verhandelbaar | 5,48% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yan Chun Li
FOU | Founder | 55 | - |
Shujun Liu
CEO | Chief Executive Officer | 71 | 30-11-70 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shujun Liu
CEO | Chief Executive Officer | 71 | 30-11-70 |
Yan Chun Li
FOU | Founder | 55 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,54% | 795 mld. | |
+41,11% | 627 mld. | |
-7,20% | 350 mld. | |
+18,67% | 328 mld. | |
+7,48% | 294 mld. | |
+17,74% | 245 mld. | |
+1,23% | 222 mld. | |
+11,82% | 215 mld. | |
+3,64% | 160 mld. |